Five months before the Food and Drug Administration issued a health warning on puberty blockers widely used off-label to treat minors with gender confusion, undermining a Department of Health and Human Services office that claimed “early gender affirming care is crucial to overall health and well-being,” an FDA leader acknowledged other health concerns.
Pediatric patients exposed to “gonadotropin-releasing hormone agonists,” most with central precocious puberty (CPP) and “a handful … transgender kids using the drugs off-label,” had an “increased risk of depression and suicidality, as well as increased seizure risk,” Division of General Endocrinology clinical team leader Shannon Sullivan told colleagues.
Read the full story